Merck Loses Appeal in Antibiotic Cubicin Patent Case
•
0 likes•129 views
In a new litigation in the patent and trademark arena, the federal appeals court invalidated Merc’s four of 5 patents pertaining to Cubicin, a drug used to treat various infections in human body. With this judgment, Merck & Co’s four of five patents for the antibiotic Cubicin will be invalidated which it got through its acquisition of Cubist Pharmaceuticals Inc. The move will offer competitors with a chance to come-up with low-cost, generic version of the drug which was making $1 bn yearly in the United States.
